In 2019, Avara refocused the business on its core capabilities within Oral Solid Dose and Sterile and this resulted in an annual EBITDA of $30.7M (unaudited), at 15% on revenues of $203M, with positive contributions from every Avara facility.

During the year, Avara committed significant investment to its facilities to further enhance capabilities, including; the ability to handle bi-/tri-layer tablet compression; hot melt technology; increased encapsulation capacity; automated visual inspection; and obtaining DEA licensing to support Schedule II and III controlled drug products. All regulatory inspections and client audits were 100% successfully completed.

In 2020, the group is committed to work relentlessly to serve its clients, invest in its people and in new capabilities, and pursue its strategy of organic growth and selective acquisition.